Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStone, Cosby A-
dc.contributor.authorTrubiano, Jason A-
dc.contributor.authorColeman, David T-
dc.contributor.authorRukasin, Christine R F-
dc.contributor.authorPhillips, Elizabeth J-
dc.identifier.citationAllergy 2020; 75(2): 273-288-
dc.description.abstractEven though 8-25% of most populations studied globally are labeled as penicillin allergic, most diagnoses of penicillin allergy are made in childhood and relate to events that are either not allergic in nature, are low-risk for immediate hypersensitivity, or are a potential true allergy that has waned over time. Penicillin allergy labels directly impact antimicrobial stewardship by leading to use of less effective and broader spectrum antimicrobials and are associated with antimicrobial resistance. They may also delay appropriate antimicrobial therapy, and lead to increased risk of specific adverse healthcare outcomes. Operationalizing penicillin allergy de-labeling into a new arm of antimicrobial stewardship programs (ASPs) has become an increasing global focus. We performed an evidence-based narrative review of the literature of penicillin allergy label carriage, the adverse effects of penicillin allergy labels and current approaches and barriers to penicillin allergy de-labeling. Over the period 1928-2018 in Pubmed and Medline, search terms used included "penicillin allergy" or "penicillin hypersensitivity" alone or in combination with "adverse events", "testing", "evaluation", "effects", "label", "de-labeling", "prick or epicutaneous" and "intradermal" skin testing, "oral challenge or provocation" "cross-reactivity" and "antimicrobial stewardship." This article is protected by copyright. All rights reserved.-
dc.titleThe Challenge of De-labeling Penicillin Allergy.-
dc.typeJournal Article-
dc.identifier.affiliationInstitute for Immunology & Infectious Diseases, Murdoch University, Murdoch, Western Australia, 6150en
dc.identifier.affiliationDepartment of Pharmacology, Vanderbilt University School of Medicineen
dc.identifier.affiliationDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Centeren
dc.identifier.affiliationDepartment of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Infectious Diseases and Centre for Antibiotic Allergy and Research, Peter MacCallum Cancer Centre, Melbourne, VIC AUSen
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.affiliationThe National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, VIC, AUSen
dc.identifier.affiliationDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USAen
dc.identifier.affiliationDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USAen
dc.identifier.affiliationCentre for Antibiotic Allergy and Research-
dc.type.austinJournal Article-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en- Diseases- (University of Melbourne)- for Antibiotic Allergy and Research-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jan 29, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.